Skip to main content
SpringerLink
Log in

The Oesophageal Mucosa: To Barrett’s and Beyond – The Genesis of Oesophageal Injury and Cellular Mutations

  • Chapter
  • First Online:
Esophageal and Gastric Disorders in Infancy and Childhood

  • 68 Accesses

Abstract

Gastro-oesophageal reflux (GER) is a normal physiological phenomenon in infants and young children, occurring as a consequence of immaturity, a transient relaxation of the lower oesophageal sphincter and the relative short length of intra-abdominal oesophagus. Gastro-oesophageal reflux disease (GERD) can be defined as reflux leading to symptoms and/or complications and may be seen in infants or older children. Reflux of gastric contents in GERD is frequent during the day but is more common after feeds and when recumbent. Normal mechanisms tend to clear the refluxate in the oesophagus quickly, thus avoiding any mucosal damage or injury. In some conditions such as oesophageal atresia, there may be delayed oesophageal clearance, prolonging the time the refluxate is in contact with the oesophageal mucosa.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N Engl J Med. 1976;295(9):476–80.

    Article  CAS  PubMed  Google Scholar 

  2. Spechler SJ. Clinical practice. Barrett’s esophagus. N Engl J Med. 2002;346:836–84.

    Article  PubMed  Google Scholar 

  3. Tytgat GNJ. Oleso knowledge: the esophageal mucosa. 1994. http://www.hon.ch/OESO/Vol_3_Eso_Mucosa/300_Chapters.html.

  4. Jankowski J, Wright N, Metltzer S, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154(4):965–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Reid BJ, Sanchez CA, Blount PL, et al. Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119–29.

    Article  CAS  PubMed  Google Scholar 

  6. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett’s esophagus. Cancer Epidemiol Biomark. 1996;5:457–9.

    CAS  Google Scholar 

  7. Lord R, Salonga D, Danenberg K, et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4(2):135–42.

    Article  CAS  PubMed  Google Scholar 

  8. Morales C, Lee E, Shay J, et al. In situ hybridization for the detection of telomerase RNA in the progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer. 1998;83:652–9.

    Article  CAS  PubMed  Google Scholar 

  9. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945–52.

    Article  CAS  PubMed  Google Scholar 

  10. Lao-Sirieix P, Roy A, Worrall C, et al. Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):288–93.

    Article  CAS  PubMed  Google Scholar 

  11. Lisa A, Rumen K, Michael TB, et al. Deletion at fragile sites is a common and early event in Barrett’s esophagus. Mol Cancer Res. 2010;8:1084–94.

    Article  CAS  Google Scholar 

  12. Stemmermann G, Heffelfinger S, Noffsinger A, et al. The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol. 1994;25(10):968–81.

    Article  CAS  PubMed  Google Scholar 

  13. Neshat K, Sanchez CA, Galipeau PC, et al. Barrett’s esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol. 1994;59:577–83.

    Article  CAS  PubMed  Google Scholar 

  14. Skinner KA. Oleso knowledge, Barrett’s esophagus. 2003. http://www.hon.ch/OESO/Vol_6_Barrett_s_Esophagus/607_Markers.html.

  15. Zhuang Z, Vortmeyer AO, Mark EJ, et al. Barrett’s esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res. 1996;56:1961–4.

    CAS  PubMed  Google Scholar 

  16. Powell SM, Papadopoulos N, Kinzler KW, et al. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology. 1994;107:1759–63.

    Article  CAS  PubMed  Google Scholar 

  17. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett’s esophagus. Oncogene. 1996;13:1867–73.

    CAS  PubMed  Google Scholar 

  18. Chevfec G, Schnell T, Sontag S. Barrett’s esophagus, A preneoplastic disorder. Am J Clin Pathol. 1992;98:5–7.

    Google Scholar 

  19. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer. J Am Med Assoc. 2002;287:1972–81.

    Article  Google Scholar 

  20. Xiao H, Li T-K, Yang J-M, et al. Acidic pH induces topoisomerase II-mediated DNA damage. Proc Natl Acad Sci U S A. 2003;100(9):5205–10.

    Google Scholar 

  21. Jankowski JA, Harrison RF, Perri I, et al. Barrett’s metaplasia. Lancet. 2000;356:2079–85.

    Article  CAS  PubMed  Google Scholar 

  22. Wild CP, Hardie LJ. Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rav Cancer. 2003;3:676–84.

    Article  CAS  Google Scholar 

  23. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinom. N Engl J Med. 1999;340:825–31.

    Article  CAS  PubMed  Google Scholar 

  24. Mayne ST, Dubrow R, et al. Nutrient intake and risk of subtypes of oesophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055–62.

    CAS  PubMed  Google Scholar 

  25. Chen HL, Ward MH, Graubard BI, et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr. 2002;75:137–44.

    CAS  PubMed  Google Scholar 

  26. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol. 2001;96:331–7.

    Article  CAS  PubMed  Google Scholar 

  27. Dixon MF, Neville PM, Mapstone MP, et al. Bile reflux gastritis and Barrett’s oesophagus: further evidence of a role for duodenogastro-oesophageal reflux? Gut. 2001;49:359–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Orlando RC. Mechanisms of epithelial injury and inflammation in gastrointestinal diseases. Rev Gastroenterol Disord. 2002;2:S2–8.

    PubMed  Google Scholar 

  29. Jolly AJ, Wild CP, Hardie LJ. Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis. 2004;19(4):319–24.

    Article  CAS  PubMed  Google Scholar 

  30. Olyaee M, Sontag S, Salman W, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett’s oesophagus. Gut. 1995;37:168–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487–96.

    Article  CAS  PubMed  Google Scholar 

  32. Iijima K, Henry E, Moriya A, et al. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. J Gastroenterol. 2002;122:1248–57.

    Article  CAS  Google Scholar 

  33. Wetscher GJ, Hinder RA, Klingler P, et al. Reflux esophagitis in humans is a free radical event. Dis Esophagus. 1997;10:29–32.

    CAS  PubMed  Google Scholar 

  34. Fountoulakis A, Martin IG, White KLM, et al. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett’s esophagus. Dig Dis Sci. 2004;49:914–9.

    Article  CAS  PubMed  Google Scholar 

  35. Chen X, Ding YW, Yang G, et al. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis. 2000;21:257–63.

    Article  CAS  PubMed  Google Scholar 

  36. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fitzgerald RC, Omary MB, Triadafilopoulos G. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett’s esophagus. Am J Physiol Gastrointest Liver Physiol. 1998;38:G47–55.

    Google Scholar 

  38. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology. 1999;117(2):327–35.

    Article  CAS  PubMed  Google Scholar 

  39. Kaur BS, Ouatu-Lascar R, Omary MB, et al. Bile salts induce or blunt cell proliferation in Barrett’s esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol. 2000;278:G 1000–9.

    CAS  Google Scholar 

  40. Souza RF, Shewmake K, Terada LS, et al. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett’s esophagus. Gastroenterology. 2002;122:299–307.

    Article  CAS  PubMed  Google Scholar 

  41. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg. 1998;2:333–41.

    Article  CAS  PubMed  Google Scholar 

  42. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg. 2000;231:303–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Debruyne PR, Bruyneel EA, Li X, et al. The role of bile acids in carcinogenesis. Mutat Res. 2001;480/481:359–69.

    Article  Google Scholar 

  44. Wang HB, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–53.

    Article  CAS  PubMed  Google Scholar 

  45. Chen XX, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119–29.

    Article  CAS  PubMed  Google Scholar 

  46. Mrasek K, Schoder C, Teichmann AC, et al. Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int J Oncol. 2010;36(4):929–40.

    PubMed  Google Scholar 

  47. Durkin SG, Ragland RL, Arlt MF, et al. Replication stress induces tumor-like microdeletions FHIT/FRA3B. Proc Natl Acad Sci USA. 2008;105(1):246–51.

    Article  CAS  PubMed  Google Scholar 

  48. Skinner DB, Walther BC, Riddell RH, et al. Barrett’s esophagus. Comparison of benign and malignant cases. Ann Surg. 1983;198:554–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Harle IA, Finley RJ, Belsheim M, et al. Management of adenocarcinoma in a columnar-lined esophagus. Ann Thorac Surg. 1985;40:330–6.

    Article  CAS  PubMed  Google Scholar 

  50. Radigan LR, Glover JL, Shipley FE, et al. Barrett esophagus. Arch Surg. 1977;112:486–91.

    Article  CAS  PubMed  Google Scholar 

  51. Ransom JM, Patel GK, Clift SA, et al. Extended and limited types of Barrett’s esophagus in the adult. Ann Thorac Surg. 1982;33:19–27.

    Article  CAS  PubMed  Google Scholar 

  52. Brand DL, Ylvisaker JT, Gelfanc M, et al. Regression of columnar esophageal (Barrett’s) epithelium after anti-reflux surgery. N Engl J Med. 1980;302:844–8.

    Article  CAS  PubMed  Google Scholar 

  53. Endo M, Kobayashi S, Kozu T, et al. A case of Barrett epithelization followed up for five years. Endoscopy. 1974;6:48–51.

    Article  Google Scholar 

  54. Naef AP, Savary M, Ozello L, et al. Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70:826–35.

    CAS  PubMed  Google Scholar 

  55. Starnes VA, Adkins RB, Ballinger JF, et al. Barrett’s esophagus. A surgical entity. Arch Surg. 1984;119:563–7.

    Article  CAS  PubMed  Google Scholar 

  56. Dooner J, Cleator IG. Selective management of benign esophageal strictures. Am J Gastroenterol. 1982;77:172–7.

    CAS  PubMed  Google Scholar 

  57. Mangla JC, Schenk EA, Desbaillets L et al. Pepsin secretion, epsinogen and gastrin in “Barrett’s esophagus”: clinical and morphological characteristics. Gastroenterology. 1976;70:669–76.

    Google Scholar 

  58. Stein HJ, Siewert JR, Holscher AH et al. Thirty fifth annual meeting of the Society of Surgery of the Alimentary Tract, New Orleans; 1976.

    Google Scholar 

  59. McCallum RW, Polepalle S, Davenport K, et al. Role of anti-reflux surgery against dysplasia in Barrett’s esophagus. Gastroenterology. 1991;100:A 121.

    Google Scholar 

  60. Pearson FG, Cooper JD, Patterson GA, et al. Peptic ulcer in acquired columnar-lined esophagus: results of surgical treatment. Ann Thorac Surg. 1987;43:241–4.

    Article  CAS  PubMed  Google Scholar 

  61. Williamson WA, Ellis Jr FH, Gibb SP, et al. Effect of antireflux operation on Barrett’s mucosa. Ann Thorac Surg. 1990;49:537–42.

    Article  CAS  PubMed  Google Scholar 

  62. McDonald ML, Trastek VF, Allen MS, et al. Barretts’s esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? Thorac Cardiovasc Surg. 1996;111:1135–8.

    Article  CAS  Google Scholar 

  63. Cameron AJ, Ott BJ, Payne WS, et al. The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med. 1985;313:857–9.

    Article  CAS  PubMed  Google Scholar 

  64. Hameeteman W, Tytgat GN, van Houthoff HJ et al. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249–56.

    Google Scholar 

  65. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett’s esophagus. J Cancer Res Clin Oncol. 1985;110:145–52.

    Article  CAS  PubMed  Google Scholar 

  66. Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology. 1988;94:81–90.

    Article  CAS  PubMed  Google Scholar 

  67. Van Sandick JW, van Lanschot JJB, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998;43:216–22.

    Article  PubMed  PubMed Central  Google Scholar 

  68. DeMeester SR, Campos GMR, DeMeester TR, et al. The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg. 1998;228:547–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Eckardt VF, Kanzler G, Bernhard G, et al. Life expectancy and cancer risk in patients with Barrett’s esophagus: a prospective controlled investigation. Am J Med. 2001;111:33–7.

    Article  CAS  PubMed  Google Scholar 

  70. Schnell TG, Sontag SJ, Chejfec C, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–19.

    Article  CAS  PubMed  Google Scholar 

  71. Altorki NK, Skinner DB. Adenocarcinoma in Barrett’s esophagus. Sem Surg Oncol. 1990;6:274–8.

    Article  CAS  Google Scholar 

  72. Thiesen J, Nigro JJ, Peters JH, et al. Chronology of the Barrett’s metaplasia-dysplasia-carcinoma sequence. Dis Esophagus. 2004;17:67–70.

    Article  Google Scholar 

  73. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s Esophagus.The AGA Chicago Workshop. Gastroenterology. 2004;127:310–30.

    Article  PubMed  Google Scholar 

  74. Coper GS, Yuan Z, Chak A, et al. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer. 2002;95:32–8.

    Article  Google Scholar 

  75. Kearney DJ, Crump C, Maynard C, et al. A case-control study of endoscopy and mortality from 57: adenocarcinoma of the esophagus or gastric cardia in persons with GERD. Gastrointest Endosc. 2003;57:823–9.

    Article  PubMed  Google Scholar 

  76. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–53.

    Article  CAS  PubMed  Google Scholar 

  77. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–86.

    Article  PubMed  Google Scholar 

  78. Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gatroenterol Hepatol. 2004;2(10):868–79.

    Article  Google Scholar 

  79. Corley DW. Barrett’s esophagus surveillance and risk of death from esophageal adenocarcinoma: a case-control study. Digestive disease week; Abstract 90. 2010.

    Google Scholar 

  80. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–31.

    Article  PubMed  Google Scholar 

  81. Eloubeide MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33(4):306–9.

    Article  Google Scholar 

  82. Gerson LB, Edson R, Lavori PW, et al. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005–12.

    Article  CAS  PubMed  Google Scholar 

  83. Conio M, Filiberti R, Blanchi L, et al. Risk factors for Barrett’s esophagus: a case-control study. Int J Cancer. 2002;97:225–9.

    Article  CAS  PubMed  Google Scholar 

  84. Kenneth K, Wang MD, Richard E, et al. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastrenterol. 2008;103:788–97.

    Article  Google Scholar 

  85. Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, Qureshi WA, Rajan E, Fanelli R, Wheeler-Harbaugh J, Baron TH, Faigel DO. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Standards of Practice Committee, American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 2006;63:570–80.

    Google Scholar 

  86. Hanna S, Rastogi A, Weston AP, et al. Detection of Barrett’s esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol. 2006;101:1416–20.

    Article  PubMed  Google Scholar 

  87. Falk GW, Skacel M, Gramlich TL, et al. Fluorescence in situ hybridization of cytologic specimens from Barrett’s esophagus: a pilot feasibility study. Gastrointest Endosc. 2004;60(1):280–4.

    Article  PubMed  Google Scholar 

  88. Brankley SM, Wang KK, Harwood AR, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett’s esophagus. J Mol Diagn. 2006;8(2):260–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Sharma P, Rastojg A, Esquivel R, et al. Accuracy of wireless capsule endoscopy for the detection of Barrett’s esophagus. Gastroenterology. 2006;130(4):A 262. S1812.

    Google Scholar 

  90. Lin O, Schembre DB, et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett’s esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc. 2007;65(4):577–83.

    Article  PubMed  Google Scholar 

  91. Goda K-I, Tajiri H, Ikegami M, et al. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett’s adenocarcinoma. Gastrointest Endosc. 2007;65(1):36–46.

    Article  PubMed  Google Scholar 

  92. Anagnostopoulos GD, Yao K, Kaye P, et al. Novel endoscopic observation in Barrett’s oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther. 2007;26(3):501–7.

    Article  CAS  PubMed  Google Scholar 

  93. Ross AS, Noffisinger A, Waxman I, et al. Narrow band imaging directed EMR for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2007;65(1):166–9.

    Article  PubMed  Google Scholar 

  94. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett’s esophagus. Gastrointest Endosc. 2006;64(2):167–75.

    Article  PubMed  Google Scholar 

  95. Kara MA, Peters FP, Fockens P, et al. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett’s esophagus. Gastrointest Endosc. 2006;64(2):176–85.

    Article  PubMed  Google Scholar 

  96. Ragunath K, Krasner N, Raman VS, et al. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett’s esophagus. Endoscopy. 2003;35(12):998–1003.

    Article  CAS  PubMed  Google Scholar 

  97. Lim CH, Rotimi O, Dexter SPL, et al. Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2006;64(2):195–9.

    Article  PubMed  Google Scholar 

  98. Horwhat JD, Maydonovitch CL, Ramos F, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastrornterol. 2007;102(10):497–506.

    Article  Google Scholar 

  99. Evans JA, Bouma BE, Bressner J, et al. Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc. 2007;65(1):50–6.

    Article  PubMed  Google Scholar 

  100. Kiesslich R, Gossner L, Goetz M, et al. In vivo histology of Barrett’s esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol. 2006;4(8):979–87.

    Article  PubMed  Google Scholar 

  101. Rabinovitch P, Longton G, Blount P, et al. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Reid B, Prevo L, Galipeau P, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Lao-Sirieix P, Lovat L, Fitzgerald RC. Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance. Clin Cancer Res. 2007;13(2):659–65.

    Article  CAS  PubMed  Google Scholar 

  104. Dunn JM, Mackenzie GD, Oukrif D, et al. Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett’s oesophagus following photodynamic therapy. Br J Cancer. 2010;102(11):1608–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Kuroki T, Fujiwara Y, Nakamori S, et al. Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer. 1995;72(2):383–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Jorgensen T, Berner A, Kaalhus O, et al. Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Res. 1195;55(9):1817–9.

    Google Scholar 

  107. Futamura N, Nakamura S, Tatematsu, et al. Clinicopathologic significance of sialyl Le(x) expression in advanced gastric carcinoma. Br J Cancer. 2000;83(12):1681–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Bird-Lieberman EL, Lao-Sirieix P, Mulholland HG et al. Phase 2 and phase 3 multicentre studies demonstrate the potential for glycans as predictive biomarkers for Barrett’s oesophagus. Gut. 2011;Suppl 60:A169–70.

    Google Scholar 

  109. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology. 2012. doi:10.1053/j.gastro.2012.06.041.

    PubMed  Google Scholar 

  110. Overholt B, Lightdale C, Wang K, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–98.

    Article  PubMed  Google Scholar 

  111. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62:24–30.

    Article  PubMed  Google Scholar 

  112. Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus. Gastrointest Endosc. 2005;61:232–40.

    Article  PubMed  Google Scholar 

  113. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;2007:185–95.

    Article  Google Scholar 

  114. Nigro JJ, Hagen JA, DeMeester, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg. 1999;230:433–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Oh DS, Hagen JA, Chandrasoma PT et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg. 2003;203(2):152–61.

    Google Scholar 

  116. Luketich JD, Landreneau RJ. Minimally invasive resection and mechanical cervical esophagogastric anastomotic techniques in the management of esophageal cancer. J Gastrointest Surg. 2004;8(8):927–9.

    Article  PubMed  Google Scholar 

  117. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2007;132:1226–33.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Surgery, Christchurch Hospital, Second Floor Parkside East, Riccarton Avenue, Private Bay 4710, Christchurch, Canterbury, New Zealand

    N. Haider, A. Day & Spencer W. Beasley

Authors
  1. N. Haider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Day
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Spencer W. Beasley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Spencer W. Beasley .

Editor information

Editors and Affiliations

  1. Medical University of Graz, Graz, Austria

    Holger Till

  2. Sheffield Children’s Hospital, Paediatric Gastroenterology Centre, Sheffield, United Kingdom

    Mike Thomson

  3. Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA

    John E. Foker

  4. Department Surgery, University of Missouri, Kansas City Children’s Mercy Hospital, Kansas City, Missouri, USA

    George W. Holcomb III

  5. University of Arizona, Tucson, Arizona, USA

    Khalid M. Khan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Haider, N., Day, A., Beasley, S.W. (2017). The Oesophageal Mucosa: To Barrett’s and Beyond – The Genesis of Oesophageal Injury and Cellular Mutations. In: Till, H., Thomson, M., Foker, J., Holcomb III, G., Khan, K. (eds) Esophageal and Gastric Disorders in Infancy and Childhood. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11202-7_73

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11202-7_73

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11201-0

  • Online ISBN: 978-3-642-11202-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation